Home / Health / Mounjaro Price Hike Drives 600% Surge in Ozempic Sales
Mounjaro Price Hike Drives 600% Surge in Ozempic Sales
23 Aug
Summary
- Mounjaro weight-loss jab cost to triple in UK
- Ozempic sales surge by 600% as Novo Nordisk shares rise
- Eli Lilly's Mounjaro sales fall after Trump's clampdown
In the weeks leading up to August 23rd, 2025, the UK has seen a dramatic shift in the weight-loss medication market. The cost of Mounjaro, a popular weight-loss jab, is set to treble in September, from £122 to £330 per dose. This has led to a surge in demand for Ozempic, a rival drug produced by the Danish pharmaceutical company Novo Nordisk.
Sales of Ozempic have skyrocketed by 600% in the past few months, while Novo Nordisk's shares have also risen significantly. Conversely, the shares of Eli Lilly, the US-based company behind Mounjaro, have fallen dramatically following a clampdown by former President Donald Trump on the so-called "foreign freeloaders" who rely on the US to pay more for medicine.
The price hike for Mounjaro has left many Brits, an estimated 500,000 of whom are currently taking the drug via private prescription, facing a difficult choice. They must now decide between managing their weight and long-term health or their finances, as the prospect of going cold turkey or paying the new, higher price is not an appealing one.
The UK government has already begun plans to roll out Mounjaro on the National Health Service (NHS), but this was a tall order even before the latest price increase. The National Institute for Health and Care Excellence (NICE) had warned that the implementation would take three years, during which time 3.4 million people in England would become eligible for the free jabs.
